GlobeNewswire Inc | Nov 2, 2021 07:30AM EDT

November 02, 2021

LAUSANNE, Switzerland, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announces that new data on its investigational Alzheimers disease (AD) candidates semorinemab, ACI-35.030 and ACI-24 will be featured in the scientific program of the Clinical Trials on Alzheimers Disease (C-TAD) Conference, taking place virtually and in person in Boston, on November 9-12, 2021.

Scientific updates at CTAD 2021

Semorinemab monoclonal anti-tau antibodyTitle: Phase 2 Trial of Semorinemab in Mild-to-Moderate Alzheimers Disease (Lauriet): Topline resultsPresenter: late-breaking readout roundtable by Cecilia Monteiro Date: Wednesday November, 10 I 10.50am-11.20am EST I In-person session streamed live in the digital platform of CTAD I Available on demand 48 hours after the session

ACI-35.030 Anti-pTau VaccineTitle: ACI-35.030, a novel anti-phospho-Tau vaccine for the treatment of Alzheimers Disease: Interim Phase 1b/2a data on safety, tolerability and immunogenicityPresenter: oral presentation by Johannes Streffer Date: Friday, November 12 I Available on demand in the digital platform of CTAD from 08:00am EST

ACI-24 anti-beta amyloid vaccineTitle: ACI-24, an anti-beta amyloid vaccine, in patients with mild Alzheimers disease: Results of a phase 2, randomized, double-blind, placebo-controlled studyPresenter: Poster P44 presented by Olivier SolDate: November 9-12 I Available on the digital platform of CTAD at all times

About AC Immune SA AC Immune SAis clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimers disease, Parkinsons disease, and NeuroOrphan indications driven by misfolded proteins. The Companys two clinically validated technology platforms, SupraAntigenand Morphomer, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials.AC Immunehas a strong track record of securing strategic partnerships with leading global pharmaceutical companies includingGenentech, a member of the Roche Group, Eli Lilly and Company, andJanssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3billionin potential milestone payments.

SupraAntigenis a registered trademark ofAC Immune SAin the following territories: AU, EU, CH, GB, JP and RU. Morphomeris a registered trademark ofAC Immune SAin CN, CH, GB, JP, and NO.

For further information, please contact:

Media Relations Investor RelationsSaoyuth Nidh Yves Kremer, Ph.D.AC Immune AC ImmunePhone: +41 21 345 91 34 Phone: +41 21 345 91 90Email: saoyuth.nidh@acimmune.com Email: yves.kremer@acimmune.com U.S. Media U.S. InvestorsShani Lewis Corey Davis, Ph.D.LaVoieHealthScience LifeSci AdvisorsPhone: +1 609 516 5761 Phone: +1 212 915 2577Email: slewis@lavoiehealthscience.com Email:cdavis@lifesciadvisors.com

Forward looking statementsThis press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immunes strategies or expectations. In some cases, you can identify these statements by forward-looking words such as may, might, will, should, expects, plans, anticipates, believes, estimates, predicts, projects, potential, outlook or continue, and other comparable terminology. Forward-looking statements are based on managements current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions Item 3. Key Information Risk Factors and Item 5. Operating and Financial Review and Prospects in AC Immunes Annual Report on Form 20-F and other filings with theSecurities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, andAC Immunedoes not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.